trial · primary record
SNV1521
Pancreatic Cancer
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 40 |
| Primary completion | 2029-06-01 |
| Primary endpoint | Safety and tolerability of SNV1521 plus daraxonrasib: treatment-emergent adverse events, serious adverse events, and dose-limiting toxicities |
| Registry ID | NCT07756281 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:31:47.233Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07756281
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.